Can tirzepatide cause constipation?
This site's tirzepatide studies do not publish a counted constipation percentage. SURMOUNT-1 reported weight in 2,539 adults at 72 weeks (up to 20.9% average loss on 15 milligrams, versus 3.1% on a dummy shot). The SURPASS-2, SURPASS-CVOT, and SURMOUNT-OSA results cover blood sugar, major heart events, and how often breathing stops during sleep. Stomach and gut effects are the pattern for this drug family, already covered in this FAQ for diarrhea. That is not a constipation rate this page can make up. This FAQ does not invent a side-effect rate the studies do not contain. Full record at /compounds/tirzepatide.
Studies in people from the compound pages this answer belongs to
- Tirzepatide
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) 2022 PMID 35658024
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) 2021 PMID 34170647
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) 2025 PMID 41406444
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.